FEMASYS INC. - COMMON STOCK

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

08 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

27 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

20 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

17 May 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

16 May 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

09 May 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

07 May 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

18 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

21 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

20 Mar 2024 08:15:00 By Nasdaq GlobeNewswire

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

13 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

06 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

28 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

06 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

26 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

23 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

15 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

30 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

28 Nov 2023 08:30:00 By Nasdaq GlobeNewswire